Retinal toxicity of ISIS 2922 and ISIS 4015, phosphorothioate oligonucleotides complementary to human cytomegalovirus (CMV) and herpes simplex virus (HSV) RNA, were evaluated. The intravitreal concentration of ISIS 2922 found not to cause permanent toxic changes in the rabbit retina was 10 mM and in the pig retina, 5 mM. The 3 mM concentration was associated with a transient inflammatory response, and 1 mM caused no retinal toxicity or inflammation. ISIS 4015 showed very mild toxicity with no permanent retinal changes and very mild inflammation at doses of 10 mM; this dose was effective in ameliorating or preventing HSV-1 retinitis when injected 1 day and 1 week prior to virus inoculation. These oligonucleotides have a low intraocular therapeutic index. Attempts to improve the therapeutic index of these compounds are indicated. Only a clinical trial can determine the toxicity profile of ISIS 2922 for the treatment of CMV retinitis.
Retinal toxicity of ISIS 2922 and ISIS 4015, phosphorothioate oligonucleotides complementary to human cytomegalovirus (CMV) and herpes simplex virus (HSV) RNA, were evaluated. The intravitreal concentration of ISIS 2922 found not to cause permanent toxic changes in the rabbit retina was 10 mM and in the pig retina, 5 mM. The 3 mM concentration was associated with a transient inflammatory response, and 1 mM caused no retinal toxicity or inflammation. ISIS 4015 showed very mild toxicity with no permanent retinal changes and very mild inflammation at doses of 10 mM; this dose was effective in ameliorating or preventing HSV-1 retinitis when injected 1 day and 1 week prior to virus inoculation. These oligonucleotides have a low intraocular therapeutic index. Attempts to improve the therapeutic index of these compounds are indicated. Only a clinical trial can determine the toxicity profile of ISIS 2922 for the treatment of CMV retinitis.
Antisense oligonucleotides have been shown to act as speprogression of retinitis is common. Intravitreal injections of these two antiviral drugs can be safely performed, but they are cific inhibitors of gene expression in a variety of in vitro systems. They are considered a promising new generation of drugs, poorly tolerated by patients because of the need of frequent injections [6, 7] . Recently an intravitreal sustained-release ganpotentially useful in most human diseases, including cancers and viral infections [1] .
ciclovir implant has been developed with promising results [8] .
We evaluated the intraocular tolerance of ISIS 2922, a phosTherapeutic applications of antisense oligonucleotides have been restricted by a number of difficulties, including stability, phorothioate oligonucleotide complementary to human CMV (HCMV) RNA in rabbit and pig eyes and the intraocular tolerpharmacokinetic behavior (both on the cellular and systemic level), and the high cost of industrial production [2] . One of ance of ISIS 4015, a phosphorothioate oligonucleotide complementary to herpes simplex virus type 1 (HSV-1) RNA in rabbit the advantages of intravitreal delivery of antisense agents for retinal disease is the access of the compounds to infected tissue eyes. The highest nontoxic intravitreal concentration was determined. To test the hypothesis that oligonucleotides can be used and the fact that the vitreous is not known to enzymatically destroy these compounds, which should allow longer survival to treat viral retinitis via intravitreal injection, we studied the effect of ISIS 4015 in an experimental model of induced HSVof the intact antisense compound [3] .
Significant interest exists in the use of locally administered 1 retinitis. Because there is no appropriate animal model for HCMV retinitis, we did not evaluate the efficacy of ISIS 2922 antiviral drugs given by intravitreal injection for viral retinitis, particularly cytomegalovirus (CMV) retinitis in AIDS patients [9] . The in vitro specificity and potency of ISIS 2922 suggest that it may be useful for the treatment of HCMV [10] . because of toxicity (which may be reversible) and development of resistance to systemic anti-CMV drugs [4, 5] . Antiviral resistance to ganciclovir or foscarnet has been described in patients Materials and Methods taking these medications for several months or longer, and
The phosphorothioate oligonucleotides, ISIS 4015 and ISIS 2922, were synthesized on a solid-phase DNA synthesizer as described [11] . One lot of ISIS 2922 drug substance was purified by preparative SAX is the equivalent of reference grade material form (SAX / oligo cont) and a nonpurified form (SAX Baseline and follow-up examinations consisted of body weight, slit and filter-sterilized. The osmolality was adjusted to Ç300 mOsm.
lamp biomicroscopy, and funduscopic examinations via indirect The endotoxin content of all lots of drugs met drug substance ophthalmoscopy. Animals had postoperative examinations at 1, 3, specifications for clinical testing (õ16 endotoxin units/mL).
5, and 7 days after the intraocular injection and once weekly there-ISIS 2922 has a nucleotide sequence of 5-GCGTTTGCTCTTafter until sacrifice. The fundus was photographed in selected CTTCTTGCG-3, which corresponds to nt 170,120-170,140 on animals. the HCMV (AD169 strain) genome [12] . This phosphorothioate Toxicity was assessed through examination with slit lamp and oligonucleotide is complementary to sequences present on major indirect ophthalmoscopy and histologically with light microscopy. immediate-early (IE) region 2 messenger RNA of HCMV encoding Electron microscopy was used to confirm lack of retinal toxicity 55-and 86-kDa polypeptides responsible for regulation of virus of ISIS 4015 at 10 mM final intravitreal concentration, the higher gene expression [13] . The mean EC 50 against HCMV AD169 nontoxic dose in the rabbit eye. These methods have been deis 0.37 { 0.26 mM [10] , and the mean EC 90 against HCMV is scribed [15, 16] . Inflammation and toxicity were scored histologi-Ç1-1.3 mM [14] .
cally by grading intraocular inflammation (primarily vitritis) and ISIS 4015 has a nucleotide sequence of 5-GTTGGAGACCGGthe degree of retinal inflammatory and optic nerve head infiltration GTTGGGG-3. It is complementary to the 5 noncoding region of on a 0-4 scale. In addition, permanent structural toxicity itself was HSV-1 UL29 mRNA. The UL29 open reading frame encodes a graded by the degree of destruction of the intraocular structures, single-stranded DNA binding protein that is required for HSV primarily retina, on a scale of 0-4: 0 indicated a normal retinal DNA replication. It has an EC 50 against HSV-1 (KOS strain) of histologic appearance and 4 indicated severe destruction and disor-0.2 mM in a 96-well ELISA-based antiviral assay that quantitates ganization of all retinal layers. viral DNA production and an EC 90 against HSV-1 KOS in serumEyes in the toxicity study group were examined clinically using free medium as measured by ELISA of 1 { 0.3 mM and as measlit lamp and indirect ophthalmoscopic examination. These examisured by virus yield assay of Ç3 mM. Both assays were performed nations revealed a normal appearance, inflammatory response to in serum-free media. This oligonucleotide exhibits sequence-spethe compound used, or retinal toxicity. We classified these incific antiviral activity, and some of its activity may be due to the flammatory changes into 5 groups on the basis of clinical and presence of a repetitive guanine structure (personal communicahistopathologic findings: group 1, no inflammation and a normal tion, ISIS Pharmaceuticals). retinal appearance; group 2, mild (1/) vitritis over the medullary The 80 eyes of 40 New Zealand White rabbits were used for ray and a normal retinal appearance; group 3, mild to moderate toxicity studies, and 29 eyes of 39 Dutch pigmented rabbits were (2/) vitritis, mainly over the medullary ray and optic disk, normal used for therapeutic studies. Body weights were 2.2-2.8 kg/aniretinal appearance, mild to moderate optic disk and medullary ray mal. In addition, 4 eyes of 2 micro-mini pigs (body weights of edema; group 4, vitritis (3/-4/), exudative retinal detachment, 20-25 kg) were used for confirmation of the toxicity studies done severe optic disk and medullary ray edema; group 5, cataract, iris in rabbits. For HSV-1 retinitis experiments and drug treatment, infarction, miosis, absent pupillary reaction, conjunctival injection, only 1 eye of each animal was used either with HSV-1 and ISIS severe (4/) vitritis, vitreous hemorrhage, exudative retinal detach-4015 or with only HSV-1 (control eyes). For the toxicity studies ment, severe optic disk and medullary ray edema. of ISIS 2922 and ISIS 4015, both eyes of each animal were used Treatment study of HSV-1 retinitis with ISIS 4015. We tested and injected either with drug or with BSS. Anesthetic and injection the efficacy of ISIS 4015 against HSV-1 retinitis by pretreating 1 were done as we have described [15, 16] . Therapeutic studies eye of each animal 1 day prior to HSV-1 virus inoculation with entailed evaluation of the antiviral effect of ISIS 4015 in an HSV-ISIS 4015 at one of three concentrations (3, 10, and 32 mM). In 1 retinitis rabbit model. The species, type of ISIS compound, final addition, the 10 mM dose was also injected intravitreally at various intravitreal concentration, and quantity of animals used are summatimes before virus inoculation to determine the duration of antiviral rized in table 1.
effect. These animals were compared. Controls were rabbits in Toxicity studies of ISIS 2922 and 4015. All doses used are whom only 1 eye was injected with HSV-1 and no oligonucleotides expressed in final intravitreal concentration (micromolar). The final or with HSV-1 and ganciclovir (571 mM final intravitreal concenintravitreal concentration following a 0.1-mL injection was calcutration) 1 day before virus inoculation. HSV-1 (10,000 U) was lated assuming the volume of the rabbit eye to be 1.4 mL and the inoculated directly onto the retinal surface as described [15, 17] . volume of the pig eye to be 3. over the medullary ray and optic disk), normal retinal appearinitial development of papillitis and vitritis, followed by retinitis exance, and mild to moderate optic disk and medullary ray edema.
panding to involve the entire retina by day 14) [15, 17] .
Histologically there were a moderate number of inflammatory cells in the vitreous, moderate destruction of the outer nuclear Results layer, and moderate to severe destruction of photoreceptors ( figure 1 
NOTE. Results of treatment with ISIS 4015 on focal HSV retinitis in rabbit eyes according to grading system, comparing treated and control animals. Classification was based on worst clinical presentation during course of infection. Grading was on scale of 0 (no retinitis) to 4 (fulminant retinitis). Treated animals with similar but delayed clinical presentation, compared with natural course, had 0.5 deducted from score for statistical purposes (see text).
* Study eyes were compared with those of control animals (n Å 15) using Wilcoxon rank sum test.
was no evidence of retinal toxicity (figure 2). The changes retinitis in our focal animal model has been described [13, 15] and involves focal retinitis with viral inclusions that expand were seen at 2 weeks and were less severe at 8 weeks. With two injections of SAX 0 compound 1 week apart, more severe over a 2-week period to destroy the retina. The eyes were graded using a combination of slit lamp and indirect ophthalinflammatory infiltration in the vitreous was seen and the outer retina was severely destroyed, including the outer nuclear layer moscopic, histologic, and immunopathologic criteria to accurately determine the presence and extent of retinitis as described and photoreceptors.
The 3 mM dose (either SAX 0 or SAX / oligo cont) showed above, which resulted in a grading system of 0 -4 plus retinitis.
Statistical analysis was performed with the Wilcoxon rank sum clinically minimal inflammatory cells in the vitreous and a normal retinal appearance. Histologically there were few (none test using JMP 3.0 (SAS Institute, Carey, NC). We tested for differences in grades of retinitis in treated animals compared to mild) inflammatory cells in the vitreous and a normal retina. The 1 mM dose (either SAX 0 or SAX / oligo cont) showed with controls (table 2) . The retinitis in control (untreated) animals progressed as no inflammation or toxicity. Therefore, with regard to retinal toxicity, the no-effect level was 10 mM in the rabbit, even with follows: 3 -4 days after virus inoculation, optic nerve and medullary ray congestion and small splinter-like hemorrhages on (SAX / oligo cont) material. Studies in the pig eye injected with ISIS 2922 at 5 mM the nerve head and throughout the medullary ray were observed. By day 5, small focal patches of retinitis characterized final intravitreal concentration (SAX / oligo cont) showed no inflammatory cells in the vitreous and no retinal toxicity. The by focal whitening of the retina were seen close to the injection site. Mild vitritis was also seen. By day 7, optic nerve and eyes injected with the ultrapure form (SAX / ref) at 20 mM showed clinically a severe inflammatory response (grade 4) medullary ray congestion became very severe; the retinitis spread, involving about half of the retina, and the vitreous haze and histologically a severe disorganization of the retina and numerous inflammatory cells in the vitreous. became more severe. By day 10, moderate to severe vitritis was present. The retina, when visible, presented diffuse Toxicity studies of eyes injected with ISIS 4015 showed a normal clinical appearance at 2 weeks and a normal retinal involvement. By day 14, vitreous hemorrhage and retinal detachments were commonly seen. histology in control eyes and with the 10 mM dose. This was confirmed by electron microscopic examination. With the 32
Classification of the animals was based on the worst clinical presentation of the eye during the first 14 days after virus mM dose, 2 of 3 eyes showed normal retinal histology and 1 of 3 had mild photoreceptor damage. With the 100 mM dose, inoculation. Treated animals with a similar but delayed clinical presentation, compared with the natural course, were given a all eyes showed moderate to severe outer retinal destruction, and with the 320 mM dose, all eyes showed total retinal destrucscore with 0.5 deducted for statistical purposes. Histopathologic and slit lamp examinations were used to verify the retinitis tion (figure 3). At 2 months, all the eyes with a 10 or 32 mM dose exhibited normal retinal histology and minimal inflammaand degree of infection at the time of sacrifice. We also used this classification to analyze the results of the pretreatment tory cells in the vitreous. All eyes injected with a 100 or 320 mM dose showed severe retinal destruction and dense inflamstudy.
The retinitis experiments revealed that all control animals matory cell infiltrate in the vitreous, optic nerve, and medullary ray (table 1) . that received only virus inoculation had severe retinitis (grade 4). Injection of ISIS 4015, yielding an intravitreal concentration Treatment of HSV-1 viral retinitis with ISIS 4015. The natural course and grading system that we used for HSV-1 of 32 mM, 1 day prior to virus inoculation of the retinal surface with HSV-1 resulted in a markedly attenuated retinitis that had cant amelioration of retinitis was seen. Therapy of established retinitis 3 days after virus inoculation was studied. In this scestatistically significantly less fulminant grading than that in the control animals (P õ .001). Similar experiments done with ISIS nario, 10 mM ISIS 4015 effected a very weak but still statistically significant amelioration of retinitis in 1 of 3 animals 4015 using a 10 mM final intravitreal concentration showed a therapeutic effect 1 day prior to virus inoculation (P Å .001; studied. The 3 mM dose of compound had no effect on retinitis when injected 1 day before infection of the retina (figure 5). figure 4 ) and a very weak but statistically significant therapeutic effect when injected 7 days before virus inoculation. To deterDiscussion mine the duration of effect of this dose (also the highest nontoxic dose of the compound in the rabbit eye), drug was injected Retinitis due to infection with viruses of the herpes family is the most common and most visually threatening intraocular Synthetic oligonucleotides represent a novel alternative to currently available antiviral drugs. Inhibition of viral replication in cell culture by using synthetic oligonucleotides has been reported for several viruses, including human immunodeficiency virus, HSV, influenza virus, Rous sarcoma virus, vesicular stomatitis virus, and papillomavirus [27] [28] [29] . Intravitreal administration of phosphorothioate oligonucleotide agents for retinal diseases would allow direct delivery of the compounds to infected tissue. For this reason, we wished to evaluate the toxicity and antiviral activity of this class of compounds in the eye.
ISIS 2922 is complementary to messenger RNA of the HCMV major IE transcriptional unit, which encodes several proteins responsible for regulation of virus gene expression [13, 30 -35] and has properties consistent with an antisense mechanism of action [10, 12] . The mean EC 50 of ISIS 2922 against HCMV AD169 is 0.37 { 0.26 mM [10] . Phosphorothioate oligonucleotides such as ISIS 2922 should inhibit replica- peutics to ameliorate HCMV disease. In this study, the ocular toxicity of ISIS 2922 following intravitreal injection of the compound in rabbit and pig eyes infection occurring in patients with AIDS [4, 5] . The only approved therapies currently available for HCMV retinitis, the was investigated. Three grades of material were used in the rabbit model: One lot of drug was purified only by reversemost common retinal infection in patients with AIDS, are daily intravenous or oral administration of ganciclovir or foscarnet.
phase chromatography (SAX 0 ), one lot was further purified by strong anion exchange but was found to contain another species Treatment with ganciclovir or foscarnet must be maintained, however, for the duration of the patient's life, as both drugs of compound (SAX / oligo cont), and a third lot was SAXpurified and representative of reference standard material in are virostatic, and discontinuation of therapy quickly leads to progressive infection, resulting in irreversible retinal destrucquality (SAX / ref). The drug product used for this work was formulated somewhat differently (in BSS) than drug product tion. A significant percentage of patients with AIDS cannot tolerate these systemic antiviral therapies because of toxic side used in human trials, which is formulated in bicarbonate-buffered saline (pH 8.7). Nevertheless, data from our study in effects [19, 20] .
Because of the toxicity of systemic intravenous therapy, local rabbits suggests that use of SAX / oligo cont material resulted in no retinal toxicity with 10 mM drug; for inflammation, the intraocular therapy has been used in some selected patients. An intravitreal sustained-release ganciclovir implant that can no-effect dose was 1 mM. When ultrapure (SAX / ref) material was used at 40 mM, there was mild retinal toxicity. SAX / ref release ganciclovir at a steady rate for 4 -8 months has recently been developed and may prove more effective than the current (ultrapure) will be used in future clinical trials. Most of the experiments were done in rabbits. However, in local treatments [7, 20 -22] . However, it involves one or more surgical procedures and complications can occur. Drug toxicity pig eyes, with retinal vasculature that is more similar to that in humans, the toxicity of the phosphorothioate oligonucleotide intravitreal injections of high doses of ISIS 2922. These models may be useful for developing an understanding of the mechacompounds was confirmed with high doses. ISIS 2922 injected into 3 pig eyes at two dose levels with two different grades of nisms of ISIS 2922. Future research directed at better understanding of the mechanism of ocular inflammation and toxicity material suggests that, even with contaminated material, the lack-of-effect dose level is 5 mM. With the 20 mM dose, there following intravitreal administration of ISIS 2922 in the rabbit may prove useful. Our studies suggest that the therapeutic inwas both retinal toxicity and inflammation. Due to the small number of eyes used, these data are not strongly conclusive.
dex, from the perspective of in vivo intraocular inflammation, is between 3 and 9 (1 -3/0.37) and, from the perspective of Clinical trials that are ongoing will further evaluate the safety profile and therapeutic index of ISIS 2922 in the vascularized irreversible retinal toxicity, is between 13 and 54 (5 -20/0.37). These numbers are based on the highest nontoxic dose divided human retina. Both rabbit and pig eyes showed toxicity with by the dose necessary to inhibit HCMV (mean EC 50 ) [10] . resulting in effective and specific inhibition of gene expression [1, 29, 36] . ISIS 4015 was originally designed as an antisense Studies of ISIS 2922 in pigs confirmed toxicity and inflammatory results in a holangiotic retina more similar to that of the oligonucleotide and it does have potent and specific antiviral activity. Its mechanism of action is sequence-specific but may be human.
Although the therapeutic index is relatively low, only studies related to a repetitive strings of guanine bases, indicating a combination of true antisense and nonantisense effects. Random oligoin humans can allow more precise determination of the highest tolerated dose. Unfortunately, we only used the ultrapure form nucleotide sequences did not produce antiviral effects. To test the efficacy of ISIS 4015, we elected to use an animal regarding ocular toxicity and application in clinical studies due to a new ultrapure compound of ISIS 2922 (SAX / ref) now model of HSV-induced focal progressive retinitis to evaluate the duration of action and efficacy of intravitreal injection. Our available. It is interesting that with both ISIS 2922 (anti-CMV) and ISIS 4015 (anti-HSV) compounds, intraocular inflammamodel produces a focal, nonlethal, expanding retinitis in the rabbit that spreads in a predictable manner to infect 100% of tion occurred at concentrations lower than those causing irreversible structural changes at the retina. Our studies also sugeyes inoculated. From the perspective of local intravitreal therapy for CMV or HSV retinitis, we used the highest nontoxic gest that, at least in the rabbit model, purification of these compounds causes a moderate reduction in their proinflammadose of the anti-HSV antisense and found that this dose (10 mM), when given 1 day prior to viral inoculation, did signifitory and toxic properties. Further studies with uncontaminated SAX-purified material should be performed to allow for the cantly inhibit retinitis, as did the higher tested dose (32 mM) in our treatment studies. Testing of the 10 mM dose given 1 calculation of a therapeutic index for the more clinically relevant dose form. Clearly, even the purest ISIS 2922 was toxic week before virus inoculation showed a more modest but definite amelioration of the retinitis. In our HSV-1 retinitis model, in rabbits at 40 mM. It is not possible to draw accurate conclusions as to the actual toxicity of the ultrapure reference standard we have previously shown that intravitreal ganciclovir (the same lot of compound used in this study) does have a therapeuin the rabbit.
Our studies of therapeutic effects of ISIS 4015 showed a defitic effect when given on the day of virus inoculation or early in the course of retinitis [15, 37] . The intravitreal dose we use nite antiviral effect in the retinitis model in preventing retinitis (table 2) . In some cases, the antiviral activity of oligonucleotides is equivalent to the final intravitreal concentration in the human eye after a standard 200-mg injection [6, 7] . appears to be due to an antisense mechanism of action in which oligonucleotides of defined sequence bind to complementary se-
In conclusion, we have demonstrated that there are doserelated ocular toxicities associated with intravitreal injections quences on target RNA molecules by Watson-Crick base-pairing,
